SCYNEXIS Inc. Common Stock (SCYX)

FairStock Score: 69/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at SCYNEXIS as a tiny antifungal drugmaker with 18 employees, one commercial product, and an early pipeline. Its record is wildly uneven. In fiscal year 2023, ended 2023-12-31, it reported revenue of $140.1 million, net income of $67.0 million, and diluted EPS of $1.39. By fiscal year 2024, ended 2024-12-31, revenue was $3.7 million and net loss was $21.3 million. Fiscal year 2025, ended 2025-12-31, showed revenue of $20.6 million but a net loss of $8.6 million. In fiscal Q1 2026, ended 2026-03-31, the net loss was $21.3 million; in fiscal Q2 2026, ended 2026-06-30, revenue was only $235,000, yet net income was $7.4 million and diluted EPS $0.63. That single positive quarter does not prove durable earning power. FairStock's calculations at the 2026-10-13 close of $3.99 show a negative P/E of -4.38, P/B of 0.59, ROE of -18.38%, ROCE of -20.82%, and FCF yield of -33.5%. The low P/B may tempt an asset-minded investor, but intangible-heavy biotech book value can be illusory. Debt is low at 0.03, yet FairStock's Piotroski F-Score is 3/9 and its Altman Z-Score is -4.02, warning of fragility. The Lynch category is TURNAROUND — loss in the latest year after earlier profits. A true moat is hard to see: small revenue, an early Phase I asset, and dependence on a narrow antifungal franchise. Without stable sales and positive free cash flow, this is speculation on a turnaround, not a Graham-style bargain.

In plain English: SCYNEXIS is a small biotech that sells and develops antifungal medicines. Its business looks weak and uneven: revenue and profits have swung sharply, with recent losses and cash burn. The stock price may look low compared with its stated assets, but the current business does not earn enough to make that cheapness clearly safe.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer